{
    "clinical_study": {
        "@rank": "134374", 
        "arm_group": {
            "arm_group_label": "Ceftriaxone treatment", 
            "arm_group_type": "Experimental", 
            "description": "ceftriaxone will be administered \u00e0 high dose : > or equal to 75mg/kg/day or 4 gr/day"
        }, 
        "brief_summary": {
            "textblock": "The aim of the study is to describe the concentrations of Ceftriaxone at the steady state,\n      in patients treated for meningitis, to determine pharmacokinetic parameters at high dose  in\n      this population. Additionally, we aimed to detect adverse effect, especially neurological\n      trouble related to Ceftriaxone toxicity."
        }, 
        "brief_title": "Pharmacological Study of High Doses of Ceftriaxone in Meningitidis", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Meningitis", 
            "Neurological Infections"
        ], 
        "condition_browse": {
            "mesh_term": "Meningitis"
        }, 
        "detailed_description": {
            "textblock": "Day 0 : onset of treatment by Ceftriaxone, following usual therapeutic process (French\n      Guideline) From Day 0 to Day 4 : inclusion, clinical and biological data collection,\n      electroencephalogram at baseline.\n\n      Two samples for ceftriaxone concentration monitoring :\n\n        -  Trough concentration of ceftriaxone at steady state\n\n        -  A random sample (population PK) At the end of ceftriaxone treatment : assessment of\n           tolerance and efficacy of the treatment."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hospitalized adults patients,\n\n          -  age equal or above 18\n\n          -  Patients with Community or surgical acquired neurological infections, meningitis and\n             others\n\n          -  Prescription of ceftriaxone >75mg/kg/d or >4g/d -\n\n          -  Subjects affiliated to French health insurance (social security)\n\n          -  Informed consent form signed\n\n        Exclusion Criteria:\n\n        - Patient under guardianship"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01745679", 
            "org_study_id": "RC12-0171"
        }, 
        "intervention": {
            "arm_group_label": "Ceftriaxone treatment", 
            "description": "ceftriaxone will be administered \u00e0 high dose : > or equal to 75mg/kg/day or 4 gr/day", 
            "intervention_name": "Ceftriaxone treatment", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Ceftriaxone"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Ceftriaxone", 
            "Adverse drug effects", 
            "Therapeutic monitoring", 
            "Meningitis"
        ], 
        "lastchanged_date": "December 10, 2012", 
        "location": [
            {
                "contact": {
                    "email": "nasseray@chu-nantes.fr", 
                    "last_name": "Nathalie ASSERAY, PH", 
                    "phone": "+33 2 40 08 33 16"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "state": "Loire Atlantique", 
                        "zip": "44093"
                    }, 
                    "name": "Nantes Universitary Hospital"
                }, 
                "investigator": {
                    "last_name": "Nathalie ASSERAY, PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "PiAbgueguen@chu-angers.fr", 
                    "last_name": "Pierre PiAbgueguen, PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Angers", 
                        "country": "France", 
                        "zip": "49933"
                    }, 
                    "name": "Angers Universitary Hospital"
                }, 
                "investigator": {
                    "last_name": "Pierre ABGUEGUEN, PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "thomas.guimard@chd-vendee.fr", 
                    "last_name": "Thomas GUIMARD, PH"
                }, 
                "facility": {
                    "address": {
                        "city": "La Roche/Yon", 
                        "country": "France", 
                        "zip": "85925"
                    }, 
                    "name": "La Roche/Yon hospital"
                }, 
                "investigator": {
                    "last_name": "Thomas GUIMARD, PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "f.roblot@chu-poitiers.fr", 
                    "last_name": "France ROBLOT, PU-PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Poitiers", 
                        "country": "France", 
                        "zip": "86021"
                    }, 
                    "name": "Poitiers Universitary hospital"
                }, 
                "investigator": {
                    "last_name": "France ROBLOT, PU-PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "pierre.tattevin@chu-rennes.fr", 
                    "last_name": "Pierre TATTEVIN, PH", 
                    "phone": "+33 2 99 28 43 21"
                }, 
                "facility": {
                    "address": {
                        "city": "Rennes", 
                        "country": "France", 
                        "zip": "35033"
                    }, 
                    "name": "Rennes Universitary hospital"
                }, 
                "investigator": {
                    "last_name": "Pierre TATTEVIN, PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "j.hoff@ch-saintnazaire.fr", 
                    "last_name": "J\u00e9r\u00f4me HOFF, PH"
                }, 
                "facility": {
                    "address": {
                        "city": "St Nazaire", 
                        "country": "France", 
                        "zip": "44600"
                    }, 
                    "name": "St Nazaire hospital"
                }, 
                "investigator": {
                    "last_name": "J\u00e9r\u00f4me HOFF, PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "garot@med.univ-tours.fr", 
                    "last_name": "Louis BERNARD, PU-PH"
                }, 
                "facility": {
                    "address": {
                        "city": "Tours", 
                        "country": "France", 
                        "zip": "37170"
                    }, 
                    "name": "Tours universitary hospital"
                }, 
                "investigator": {
                    "last_name": "Louis BERNARD, PU-PH", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "Therapeutic Monitoring of Ceftriaxone, Prescribed at High Doses, in the Treatment of Meningitis and Others Neurological Infections.", 
        "overall_contact": {
            "email": "nasseray@chu-nantes.fr", 
            "last_name": "Nathalie ASSERAY, PH", 
            "phone": "+33 2 40 08 33 16"
        }, 
        "overall_contact_backup": {
            "email": "dominique.navas@chu-nantes.fr", 
            "last_name": "dominique NAVAS, PH", 
            "phone": "+33 2 40 08 41 54"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France:ANSM", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "plasmatic concentration of ceftriaxone, measured at the steady state (after 48 hours of treatment at least).", 
            "safety_issue": "No", 
            "time_frame": "after at least 48 hours of ceftriaxone treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01745679"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Neurological troubles explored by electroencephalogram aiming to diagnose epileptic syndrome.", 
                "measure": "Neurological troubles", 
                "safety_issue": "Yes", 
                "time_frame": "participants will be followed for the duration of ceftriaxone treatment, an expected average of two weeks"
            }, 
            {
                "description": "Time of return to apyrexia, health complications and lenght of hospital stay   will be registered.", 
                "measure": "clinical evolution", 
                "safety_issue": "No", 
                "time_frame": "participants will be followed for the duration of ceftriaxone treatment, an expected average of 2 weeks"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}